ImpediMed
Follow
Get notifications in MyBN when activity occurs.
Upgrade your subscription to use this feature.
Industry Lists
Public Companies - non WAImpediMed Limited (IPD) is involved in designing and manufacturing of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of tissue composition and fluid status. IPD produces a family of FDA cleared and CE Marked medical devices for multiple indications including heart failure and lymphoedema.
Contact Details
Unit 1, 50 Parker Ct, PINKENBA QLD 4008
07 3860 7000
Lists and Charts
Share price
Closing price for the last 90 trading days
Powered by Morningstar ®
Total Shareholder Return as at 29/11/24
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 1644th | ImpediMed | -64% | -21% |
1740 WA (and selected non WA) listed companies ranked by
1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| th |  | ImpediMed | $13.1m |
1333 listed non wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Share Transactions
Total value as at the date of the transaction
Powered by Morningstar ®
Company Activity
| NEW ROLE: Fiona Bones, Non-Executive Director | 31 Jul 2024 |
| NEW ROLE: Janelle Delaney, Non-Executive Director | 31 Jul 2024 |
| NEW ROLE: Christine Emmanuel, Non-Executive Director | 31 Jul 2024 |
| NEW ROLE: McGregor Grant, Executive Chairman, Executive Director, Chief Financial Officer | 31 Jul 2024 |
| NEW ROLE: Parmjot Bains, Managing Director, Chief Executive Officer | 31 Jul 2024 |
| NEW ROLE: Andrew J Grant, Non-Executive Director | 31 Jul 2024 |
| NEW ROLE: T Cruickshank, | 15 Oct 2021 |
| NEW ROLE: D Schlaht, SVP R&D and Technology | 25 Nov 2020 |
| NEW ROLE: M Vigeland, Chief Financial Officer | 25 Nov 2020 |
